Novartis struck a major licensing partnership with Abogen Biosciences for its mRNA-encoded autoimmune therapy ABO2203, escalating the race to in vivo immune reset approaches. The agreement is worth $575 million upfront, with potential total value up to $7.8 billion tied to milestones and options across multiple programs, according to deal reporting tied to BIO-Europe. ABO2203 is designed as a CD19xCD3 T-cell engager intended to deplete B cells in autoimmune disease. The mRNA platform aims to direct production of the engager inside the body rather than delivering a recombinant protein, positioning it as an alternative immune-modulating modality for conditions where current options are insufficient. For Abogen, the deal provides substantial non-dilutive capital while deepening Novartis’ focus on RNA therapeutics beyond vaccines. For the broader market, it reinforces how large pharma is funding late preclinical-to-clinical platform bets through licensing structures as pipeline renewal accelerates.